Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Net Income (2016 - 2025)

Historic Net Income for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Harvard Bioscience's Net Income rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
  • As of Q3 2025, Harvard Bioscience's Net Income stood at -$1.2 million, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Net Income ranged from a high of $2.4 million in Q2 2022 and a low of -$50.3 million during Q1 2025
  • For the 5-year period, Harvard Bioscience's Net Income averaged around -$4.2 million, with its median value being -$1.3 million (2023).
  • Data for Harvard Bioscience's Net Income shows a peak YoY increase of 69048.78% (in 2022) and a maximum YoY decrease of 189411.76% (in 2022) over the last 5 years.
  • Over the past 5 years, Harvard Bioscience's Net Income (Quarter) stood at $590000.0 in 2021, then tumbled by 466.78% to -$2.2 million in 2022, then rose by 15.99% to -$1.8 million in 2023, then surged by 102.75% to $50000.0 in 2024, then tumbled by 2568.0% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q3 2025, -$2.3 million for Q2 2025, and -$50.3 million during Q1 2025.